This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abbott (ABT) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 5.10% and 1.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Abbott (ABT) Gets FDA Clearance for FreeStyle Libre 3 Reader
by Zacks Equity Research
Abbott (ABT) receives the FDA clearance for a standalone reader to be used for the FreeStyle Libre 3 iCGM system.
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $103.61, moving +1.02% from the previous trading session.
What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?
by Zacks Equity Research
Abbott Laboratories' (ABT) Established Pharmaceuticals Division (EPD) and Diabetes arm are boosting business in recent months.
Earnings Preview: Abbott (ABT) Q1 Earnings Expected to Decline
by Zacks Equity Research
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics (TGTX) Surges 22.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NOBL
The Zacks Analyst Blog Highlights T-Mobile US, Abbott Laboratories, Advanced Micro Devices, Intuit and Cintas
by Zacks Equity Research
T-Mobile US, Abbott Laboratories, Advanced Micro Devices, Intuit and Cintas are included in this Analyst Blog.
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $102.80, marking a +1.19% move from the previous day.
Top Stock Reports for T-Mobile US, Abbott Laboratories & AMD
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stock, including T-Mobile US, Inc. (TMUS), Abbott Laboratories (ABT) and Advanced Micro Devices, Inc. (AMD).
Abbott's (ABT) Epic Max Tissue Valve Receives FDA Approval
by Zacks Equity Research
Abbott's (ABT) Epic Max design optimizes patient blood flow and has a low profile that makes future cardiac interventions simpler.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $98.46 in the latest trading session, marking a +0.42% move from the prior day.
Abbott's (ABT) CardioMEMS Favors Heart Failure Management
by Zacks Equity Research
Abbott (ABT) announces key findings from meta-analysis, which shows remote pressure monitoring to be a life-extending option among heart failure patients.
Wall Street Analysts See Abbott (ABT) as a Buy: Should You Invest?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Here's Why You Should Retain Abbott (ABT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on continued growth in the core Diagnostics arm.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Abbott (ABT) Stock Moves 0.89%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $97.87, moving +0.89% from the previous trading session.
Abbott (ABT) Diabetes Arm Growth Robust Amid Macroeconomic Woes
by Zacks Equity Research
Abbott (ABT) currently forecasts total organic sales growth, excluding the impact of COVID testing-related sales, to be in the high-single digits in 2023.
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $98.55 in the latest trading session, marking a +0.37% move from the prior day.
Top Research Reports for AbbVie, NextEra Energy & ConocoPhillips
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), NextEra Energy, Inc. (NEE) and ConocoPhillips (COP).
Abbott (ABT) to Pair CGM Sensors & AID System on FDA Clearance
by Zacks Equity Research
Abbott Laboratories (ABT) receives FDA clearance for the integration of its iCGM system sensors with automated insulin delivery (AID) systems.
Is Invesco Defensive Equity ETF (DEF) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DEF
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $99.40, marking a -0.58% move from the previous day.
Abbott (ABT) Gets FDA Nod for Alinity I Laboratory Test
by Zacks Equity Research
Abbott's (ABT) Alinity i TBI lab test provides a new reliable result in 18 minutes to support clinicians in quickly assessing concussion and triaging patients.
Abbott (ABT) Reveals Favorable Data on Tricuspid Regurgitation
by Zacks Equity Research
Abbott Laboratories (ABT) demonstrates the superiority of the TriClip device in treating patients with severe, symptomatic tricuspid regurgitation.